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A B S T R A C T
Purpose: Anti-NMDAR-encephalitis is a recently described form of autoimmune encephalitis. Here, we
characterize CSF changes in Chinese patients with anti-NMDAR encephalitis, and explore the
relationship between CSF ﬁndings and disease outcome.
Methods: The presence of NMDAR antibodies in serum or CSF samples was evaluated in patients
diagnosed with encephalitis between October 1, 2010 and August 1, 2014 at the West China Hospital. All
patients fulﬁlling our diagnostic criteria were included and CSF ﬁndings were analyzed. Patient outcome
was assessed after 4, 8, 12, 16, 20, and 24 months using the modiﬁed Rankin scale (mRS).
Results: Out of 3000 people with encephalitis screened, 43 patients were anti-NMDAR antibody positive
in CSF or serum and included in this study. 62.8% of the patients identiﬁed with positive CSFs had positive
serum anti-NMDAR samples, while 100% patients with positive serum had positive CSF samples. In the
CSF white cell counts were elevated in 58.1% of cases; protein was increased in 18.6%; QAlb > Qlim(Alb)
of the blood–CSF barrier was found in 29.3%; intrathecal immunoglobulin synthesis was detected in
17.1%, and 39.5% patients exhibited increased CSF pressures. A longer follow-up period was associated
with better outcomes. There was no relationship between changes in CSF ﬁndings and outcome.
Conclusion: The sensitivity of NMDA receptor antibody testing is higher in CSF compared to serum. Other
CSF abnormalities are present in some patients with Anti-NMDAR-encephalitis, however these changes
do not appear to affect prognosis.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encepha-
litis is a newly identiﬁed antibody-mediated disorder, having
been formally recognized in 2007. Anti-NMDAR encephalitis has
been increasingly identiﬁed as a cause of autoimmune and
paraneoplastic or non-paraneoplastic encephalitis [1]. Electroen-
cephalographic (EEG) tracings typically show non-speciﬁc,
generalized slowing or epileptiform activity, and brain magnetic
resonance imaging (MRI) in 50–77% of patients is either* Corresponding author. Tel.: +86 28 8542 2549; fax: +86 28 8542 2549.
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abnormalities in various regions of the brain [2]. Despite the
severity of the disease, most patients show improvement after
intensive care support, immunotherapy, and lengthy hospital
stays with multidisciplinary care [3].
Analysis of cerebrospinal ﬂuid (CSF) is widely used for routine
neurological diagnostics in some neurological conditions to
reveal constellations suggestive for ongoing acute or chronic CNS
inﬂammation. To our knowledge, few studies have focused on
CSF changes in anti-NMDAR encephalitis. Several studies have
shown that patients with anti-NMDAR-encephalitis can have
normal or changed CSF ﬁndings. A recent study identiﬁed
abnormal CSF ﬁndings in 79% of patients [4], and a recent
review [5] of CSF revealed lymphocytic pleocytosis in more than
90% of cases, intrathecal protein increase in 33% and oligoclonal
bands in approximately 25%. In a published study on ab-LE
(antibody-associated limbic encephalitis) in anti-NMDAR-en-
cephalitis patients, elevated cell and protein counts wereserved.
Table 1
Clinical characteristic of participants in the study.
Characteristic/symptoms Patient
Age Medium, range 23 (9–39)
Sex
Female (n, %) 24 (55.8%)
Male (n, %) 19 (44.2%)
Main symptoms
Fever (n, %) 31 (72.1%)
Headache and/or dizziness (n, %) 12 (27.9%)
Psychiatric symptoms (n, %) 41 (95.3%)
Seizures (n, %) 37 (86.0%)
Abnormal movements (n, %) 15 (34.9%)
Disorders of consciousness (n, %) 29 (67.4%)
Hypoventilation (n, %) 13 (30.2%)
Treatment
First-line treatments (steroids and/or immunoglobulin) (n, %) 35 (81.4%)
Second-line treatments (rituximab, cyclophosphamide) (n, %) 2 (4.65%)
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CSF ﬁndings in this type of encephalitis in Chinese patients have
not been previously reported. Additionally, no study thus far has
analyzed the impact of abnormal CSF ﬁndings on disease
outcomes, which is critical for determining disease prognosis
and thus warrants investigation.
Therefore, the aim of the current study was to prospectively
analyze the characteristics of CSF changes in Chinese patients with
anti-NMDAR encephalitis, and to identify a potential relationship
between CSF ﬁndings and disease prognosis.
2. Patients and methods
2.1. Standard protocol approvals, registrations and patient consents
The study was approved by the Research Ethics Committee of
the Medical School of Sichuan University. Each participant
provided written informed consent prior to study enrollment.
2.2. Participants
We tested for the presence of NMDAR antibodies in serum or
CSF samples of patients with encephalitis between October 1,
2011 and August 1, 2014 at the West China Hospital. Patients
included in the study tested positive for NMDAR antibodies and met
the following inclusion criteria: (1) encephalitic signs with
psychiatric symptoms (agitation, paranoid thoughts, irritability,
or hallucinations), seizures, or focal neurological signs, (2) detection
of anti-NMDA receptor antibodies in CSF or serum. Exclusion criteria
were as follows: (1) HIV infection, meningitis, brain abscess, prion
diseases, cerebral malaria, brain tumor, or a diagnosis of a non-
infectious central nervous system disease, such as acute demyelin-
ating encephalomyelitis (ADEM). (2) Patients with laboratory
evidence of infectious encephalitis, e.g. viral, bacteria, mycobacteri-
um tuberculosis (TB), parasitic or fungal. (3) Patients diagnosed with
epilepsy prior to the onset of encephalitis. Neurologists who have
received the uniform training on the study interviewed all of the
target patients in the inpatient clinic of our center. If diagnostic
and inclusion criteria were met, a research assistant introduced
the study to the patient and obtained informed consent.
2.3. Determination of antibodies to NMDAR
CSF examinations of patients were performed within one week
of disease onset. Patient serum and CSF samples were obtained
simultaneously and were maintained and transferred on ice to the
laboratory. All specimens (serum and CSF) were evaluated for anti-
NMDAR IgG antibodies by indirect immunoﬂuorescence (IIF) using
EU 90 cells transfected with the The NMDAR1 subunit (NR1) of the
NMDAR complex and immobilized on BIOCHIPs (euroimmunAG,
Lu¨beck, Germany) as previously described [7]. Slides were
incubated with undiluted CSF samples or serum samples at a
starting dilution of 1:10, and analysis was performed according to
the manufacturer’s guidelines. Following incubation of samples
with transfected or untransfected cell lines, slides were washed
and stained with ﬂuorescein-labeled anti-human IgG antibodies
and visualized using a ﬂuorescence microscope. Samples were
classiﬁed as positive or negative based on the intensity of surface
immunoﬂuorescence of transfected cells compared to non-
transfected cells, according to the manufacturer’s suggested
recommendations for reading and interpretation.
2.4. CSF examination
Intracranial pressure was evaluated by cerebrospinal ﬂuid
pressure gauge and a pressure > 180 mm H2O was considered tobe increased. Integrated CSF analyses included total cell count,
total protein content, albumin, and IgG content in both CSF and
serum. Abnormally elevated cell counts were deﬁned as total cell
counts >5/ml without erythrocytosis and CSF protein > 500 mg/L
[6]. Evaluation of blood–CSF-barrier function was performed using
the nationally accepted parameter of age-dependent albumin-CSF/
serum-quotient (QAlb). Dysfunction was deﬁned as QAlb > Qli-
Qlim(Alb), where Qlim(Alb) was calculated as 4+ (a/15) where a
represents the patient’s age. Quantitative expressions of the
intrathecal humoral immune response were based on calculation
of the QIgG (IgG-CSF/serum quotient). The upper limits of the
reference range, Qlim(IgG), were calculated against QAlb according
to Reiber’s revised hyperbolic function. Values for QIg exceeding
Qlim (Ig) were considered to indicate intrathecal immunoglobulin
synthesis. [8] The detection of organism-speciﬁc nucleic acids in
CSF by polymerase chain reaction (PCR) was used for rapid
diagnosis of CNS infections, such as nucleic acid testing for HSV,
VZV and enteroviruses. Additionally, cultures for bacteria, tuber-
culosis, and fungus of CSF were all performed.
2.5. Evaluation of prognosis
Clinical outcome was evaluated using the modiﬁed Rankin
Scale (mRS) [9] by calling the patients at 4, 8, 12, 16, 20, and
24 months after discharge from the hospital. Good outcomes were
deﬁned as mRS score 0–2.
2.6. Statistical analysis
All analyses were performed using the SAS 9.2 software package
(SAS 2000). To compare mRS scores (follow-up at 4 months,
8 months, and 12 months) between groups, including the
abnormal CSF ﬁndings group (i.e. elevated pressures, elevated
total cell counts, and protein levels), normal CSF ﬁndings group,
serum antibody-positive group and serum antibody-negative
group, the mixed effect model was used for analysis of repeated
measurement data. A p-value (two-sided) of <0.05 was considered
as statistically signiﬁcant.
3. Results
3.1. Demographic data and characteristics of the participants
A total of 3000 people with encephalitis were screened and
43wereincluded inthisstudy.Demographicdetails of the 43 patients
with anti-NMDAR-encephalitis are provided in Table 1. The study
group was comprised of 24 (55.8%) female and 19 (44.2%) male
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presentations, including prodromal symptoms, consisting of
headache, fever, or upper respiratory-tract symptoms, and
psychiatric symptoms, sub-acute memory disturbance, seizures,
and abnormal movements (Table 1). All female patients had
undergone extensive whole body/pelvic imaging, but surprisingly
there was only one female patient with an underlying ovarian
teratoma and no other tumors were found in any other female
patient. Among the 19 males, one patient had been diagnosed
with renal carcinoma and another with choriocarcinoma and
teratoma. Participants in our study have a novel feature was the
low paraneoplastic rate 3/43 (7%). In our cohort, 36 patients
received intensive immunotherapies (e.g., steroids, intravenous
immunoglobulins, rituximab, and cyclophosphamide). After
intensive immunotherapies, the condition of thirty patients
did not continue to deteriorate, four patients refused further
treatment, and two patients died.
3.2. CSF ﬁndings within one week of anti-NMDAR–encephalitis onset
In 3000 people with encephalitis screened, there were
43 patients with anti-NMDAR antibody positive in CSF and
27 patients with anti-NMDAR antibody positive in serum. During
the patients screened, 62.8% (27/43) of patients with positive CSFs
had positive serum samples, while 100% (27/27) patients with
positive serum had positive CSF samples. None of the patients
exhibited anti-NMDAR positivity only in the serum. Totally, there
were 43 patients with anti-NMDAR antibody positive in CSF or
serum, which were included in this study according to the
inclusion criteria.
Characteristics and abnormal CSF ﬁndings of the 43 patients are
described in Table 2. Increased cranial pressure (>180 mm H2O)
was observed in 17/43 (39.5%) patients, elevated total cell counts
in CSF were reported in 25/43 (58.1%) patients, and 8/43 (18.6%)
patients exhibited elevated total protein counts. QAlb > Qlim(Alb)
was found in 12/41 (29.3%) patients, which is an indicator for
blood–CSF barrier dysfunction. Elevated QIgG was detected in 7/41
(17.1%) patients. Overall, CSF sugar and chlorine levels were
normal in 40 patients. Repeated CSF investigations in eight
patients showed that after therapy elevated total cell and protein
came back to normal.
3.3. Correlation of CSF results with prognosis
Thirty-eight of the 43 inpatients were followed for at least
4 months, during which ﬁve were lost to follow-up and two died
prior to discharge from the hospital. As shown in Fig. 1, for the ﬁrst
day in hospital, 41 out of 43 patients had baseline mRS scores
greater than or equal to 3. At the 4-month of follow-up, 27 out of
38 patients (71%) had an improved outcome (mRS 0–2). After
8 months of follow-up, 14 out of 17 patients (82%) had an improvedTable 2
CSF ﬁndings of patients with anti-NMDAR encephalitis.
CSF Units Reference range M
Intracranial pressure mmH2O <180 N
Total cell, CSF cells/ml 5 3
Total protein, CSF g/l 0.50 0
Alb, CSF g/l 0.30 0
QAlb – N.A.a 5
IgG, CSF g/l 0.04 0
QIgG – N.A.a 3
Median (with ranges) values as well as number and proportion of patients with elev
serum)*1000; IgG, CSF, IgG concentration of CSF. QIgG, (IgGCSF/IgG serum)*1000; N.A,
a Age-dependent.outcome (mRS 0–2) and 1 committed suicide after suffering from
depression. After 12 months of follow-up, 11/11 patients (100%)
had mRS scores of 0–2. The improved prognosis of the disease was
time-dependent (P < 0.05), as a longer follow-up period was
associated with better disease outcomes. After 24 months of
follow-up, all 5 patients had recovered and resumed their normal
life activities, including returning to work or school.
The comparison of mRS (at 4-month, 8-month, and 12-month
follow up) between patients with normal and abnormal CSF
ﬁndings or between serum antibody-positive and serum anti-
body-negative patients is presented in Table 3. There were no
differences in mRS scores between serum antibody-positive and
serum antibody-negative patients (P > 0.05). Furthermore, there
were no statistically signiﬁcant differences in mRS scores
between the patients with normal and abnormal CSF pressure
(P > 0.05), the patients with normal and abnormal total protein
(P > 0.05), and the patients with normal and abnormal total cell
count (P > 0.05).
4. Discussion
Of 43 patients with anti-NMDA-receptor encephalitis in our
study, presence of NMDA-antibodies, cerebral pressures, elevated
cell counts, and elevated protein counts were identiﬁed in CSF. Our
results suggest that abnormal CSF ﬁndings did not affect patients’
prognosis and that a longer follow-up period was associated with
a better outcome.
In this study we determined that all 43 patients tested were
positive for anti-NMDAR antibodies in CSF. However, only
27 patients tested positive for antibodies in serum. This result is
consistent with the observations of Dalmau and colleagues, [2]
who showed that, none of the 431 patients studied (412 with
paired serum and CSF) showed antibody positivity exclusively in
serum. Also, Titulaer et al. determined that detection of NMDAR
antibodies was more sensitive in CSF (100%) than in serum (85%;
P < 0.0001) in a comparison of 250 paired serum and CSF samples
[4,10]. However, in a previous study by Jung-Ah Lim et al. in which
both serum and CSF of 17 patients were tested for presence of
(anti-NMDAR) antibodies, 13 patients exhibited antibody positivi-
ty only in serum [11]. Irani et al. [12], determined that the absolute
levels of NMDA antibodies were higher in serum than in
cerebrospinal ﬂuid, and the analysis of Brenda et al. [7], found
signiﬁcantly higher serum antibody levels compared to CSF. The
disparity may be arisen by different methods and details of
procedure [13]. Some laboratories used commercial kits that
provide ﬁxed brain tissue and ﬁxed antigen-expressing cells may
detect nonpathogenic antibodies to intracellular and ﬁxation-
exposed epitopes, while, some employed live mammalian cells
which exposed the patients’ antibodies only to the extracellular
domains of native antigens. We have to acknowledge a limitationean Std. deviation Median range Elevated n(%)
.A.a N.A.a 17/43 (39.5)
1.31 (88.35) 10(0–540) 25/43 (58.1)
.39 (0.22) 0.32(0.22–1.40) 8/43 (18.6)
.219 (0.152) 0.141(0.0755–0.647) 10/41 (24.4)
.33 (3.55) 3.84(1.69–19.61) 12/41 (29.3)
.0421 (0.0613) 0.0274(0.0127–0.411) 12/41 (29.3)
.25 (1.50) 2.81(1.70–9.25) 7/41 (17.1)
ated values are given; Alb, CSF, albumin concentration of CSF; QAlb, (AlbCSF/Alb
 not available.
Fig. 1. Clinical outcome (mRS scores). (A) Clinical outcome in patients with abnormal ﬁndings; (B) clinical outcome in patients with normal CSF ﬁndings; (C) clinical outcome
in all patients; follow up months: 0, means the ﬁrst day patient in hospital, the baseline mRS scores.
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NMDA antibodies in CSF and serum.
Of the 43 patients from whom we obtained CSF samples, 25
(58.1%) had elevated total cell counts, and 8 (18.6%) had elevated
total protein counts, which is similar to what has been reported
in other cases. Dalmau et al.’s [14] investigation of CSF revealed
mild lymphocytic pleocytosis in 91% of cases, and intrathecal
protein increase in 32% of cases. Also, Malter et al. [6], reported
that in 14 anti-NMDAR-encephalitis patients, elevated cell
counts were reported in 2/14 (14.3%) patients and elevated
protein counts in 5/14 (35.7%) patients. And in their review of
literature, in 109 anti-NMDAR-encephalitis patients elevatedcell counts were found in 79/107 (74%) patients and elevated
protein counts in 30/101 (30%) patients. while some case series
reported slight CSF changes [1,15,16]. These studies are consis-
tent in showing that in patients with anti-NMDAR-encephalitis,
CSF ﬁndings are either normal or exhibit only slight changes. To
date, there have been no reports demonstrating a relationship
between intracranial pressure changes and anti-NMDAR en-
cephalitis; therefore, our research is the ﬁrst to show that 39.5%
of patients with anti-NMDAR encephalitis have increased
intracranial pressure.
To the best of our knowledge, few studies have reported
a relationship between CSF ﬁndings and the prognosis of
Table 3
The relationship between CSF ﬁndings and mRS scores (follow up at 4 months, 8 months and 12 months).
Variable mRS scores at 4 months mRS scores at 8 months mRS scores at 12 months
n (%) P-value n (%) P-value n (%) P-value
Pressure
Elevated 16/38 (42.1%) 0.2576 5/17 (29.4%) 0.784 4/11 (36.4%) 0.7083
Normal 22/38 (57.9%) 12/17 (70.6%) 7/11 (63.6%)
Total protein
Elevated 7/38 (18.4%) 0.5617 4/17 (23.5%) 0.0619 2/11 (18.2%) 0.4827
Normal 31/38 (81.6%) 13/17 (76.5%) 9/11 (81.8%)
Total cell count
Elevated 22/38 (57.9%) 0.066 10/17 (58.8%) 0.0653 7/11 (63.6%) 0.2388
Normal 16/38 (42.1%) 7/17 (41.2%) 4/11 (36.4%)
Antibody in serum
Positive 21/38 (55.3%) 0.2694 10/17 (58.8%) 0.9209 10/11 (90.9%) 0.9165
Negative 17/38 (44.7%) 7/17 (41.2%) 1/11 (9.1%)
P-values < 0.05 were considered statistically signiﬁcant.
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one year after discharge from the hospital, the majority of patients
had regained their independence and the ability to perform
self-care, and had returned to the workplace or to school. In
addition, we found that improved mRS scores were not signiﬁ-
cantly associated with changes in CSF ﬁndings. Based on this study,
the prognoses may not be affected by abnormal CSF ﬁndings, but
may be more related to the recovery time. Titulaer et al. [4] found
that predictors of good outcome included lower severity of
symptoms (assessed as no need for admission to an intensive
care unit), the prompt initiation of immunotherapy, and tumor
removal.
Previous studies have shown that albumin can serve as an
indicator of compromised BBB function in a variety of pathophysi-
ological conditions [17–19]. Pentylenetetrazole-induced seizures
cause disruption of the BBB, allowing penetration of large blood-
borne molecules, including albumin, into the CNS. Increased
albumin concentrations in CSF are directly due to blood–CSF
barrier dysfunction, as albumin originates exclusively from the
blood [20]. In this study, we have found that a subset of patients
exhibited blood–CSF barrier dysfunction, which illustrates the
process of cerebral inﬂammation.
In our study, the paraneoplastic rate in patients with anti-
NMDAR antibody positive in CSF or serum was 3/43 (7%), which
seems to be lower than previous reports. Irani et al. [12], reported
that there were 8/31 (26%) female patients with ovarian teratomas,
and 1/13 (8%) males with Hodgkin’s lymphoma. Also, Dalmau et al.
[14], reported 58 (59%) of 98 patients had a neoplasm. The
disparity may arise by the ethnicity differences.
Here we demonstrate that normal CSF ﬁndings do not rule out a
diagnosis of anti-NMDAR-encephalitis, but are a frequent ﬁnding
in the disease. Based on these results, we recommend that, once
anti-NMDAR-encephalitis is clinically suspected, evaluation of
NMDAR antibodies be performed, even in patients with normal
or unremarkable CSF ﬁndings. This includes patients with the
following characteristics: (1) encephalitic signs, including psychi-
atric symptoms (agitation, paranoid thoughts, irritability, or
hallucinations), (2) seizures, and (3) exclusion of viral/bacterial
etiology, especially in very young patients. Our ﬁndings encourage
physicians to screen for immune-related causes in all patients with
encephalitis, and run in parallel with other routine tests.
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